Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DSP107+ Atezolizumab · 1 trial · 1 indication
Median Overall Survival (mOS) will be estimated using Kaplan-Meier methodology as the median time from the start of study treatment to the last known date a participant was alive. Censoring rules will be applied for participants without an event at the time of analysis, and 95% confidence intervals for mOS will be provided.
| Arm | Type | Description |
|---|---|---|
| DSP107 in combination with Atezolizumab | EXPERIMENTAL | DSP107 10 mg/kg IV on Days 1, 8, and 15 of each 28-day cycle. Atezolizumab 1680 mg IV on Day 1 of each 28-day cycle. |
| Fruquintinib | ACTIVE_COMPARATOR | Participants will receive fruquintinib orally in 28-day cycles, for up to 24 cycles (96 weeks), or until disease progression, unacceptable toxicity, or study withdrawal. |
| Name | Type | Description |
|---|---|---|
| DSP107 + Atezolizumab | DRUG | DSP107 infusion begins \~30 (±10) minutes after completion of atezolizumab infusion on Day 1. |
| Fruquintinib | DRUG | 5 mg orally, once daily (with or without food), on Days 1-21 of each 28-day cycle, followed by 7 days off. |
Inclusion Criteria: 1. Are ≥ 18 years of age with a life expectancy of \> 3 months. 2. Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy...
Top 20 of 76 competitors